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Abstract 
Myocarditis is an inflammatory disease of the myocardium with a broad spectrum of clinical presentations, ranging 
from mild symptoms to severe heart failure. The course of patients with myocarditis is heterogeneous, varying 
from partial or full clinical recovery in a few days to advanced low cardiac output syndrome requiring mechanical 
circulatory support or heart transplantation. Myocarditis is a very heterogeneous disease, especially in the 
pediatric age group as worldwide disease myocarditis has been defined by the World Health 
Organization/International Society and Federation of Cardiology as an inflammatory disease of the heart muscle 
diagnosed by established histological, immunologic, and immunohistological criteria. Pediatric myocarditis 
remains challenging from the perspectives of diagnosis and management. Multiple etiologies exist, and the 
majority of cases appear to be related to viral illnesses. Enteroviruses are believed to be the most common cause, 
although cases related to adenovirus may be more frequent than suspected. The clinical presentation is extremely 
varied, ranging from asymptomatic to sudden unexpected death. A high index of suspicion is crucial. There is 
emerging evidence to support investigations such as serum N-terminal B-type natriuretic peptide levels, as well as 
cardiac magnetic resonance imaging as adjuncts to the clinical diagnosis. In the future, these may reduce the 
necessity for invasive methods, such as endomyocardial biopsy, which remain the gold standard. Management 
generally includes supportive care, consisting of cardiac failure medical management, with the potential for 
mechanical support and cardiac transplantation. Treatments aimed at immunosuppression remain controversial. 
The paediatrics literature is extremely limited with no conclusive evidence to support or refute these strategies. All 
these summarised in this article and the listed current literature showed that there is no consensus regarding 
aetiology, clinical presentation, diagnosis, and management of myocarditis in pediatric patients. 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Myocarditis, the inflammation of the muscular 
walls of the heart, remains a diagnostic challenge in 
the clinical setting because of the variability of 
presentations in the pediatric population. It has the 
potential for significant morbidity including diminished 
cardiac function and cardiac failure, occasionally 
necessitating aggressive circulatory support [1]. 
Dilated cardiomyopathy is a significant sequela of 
myocarditis and is a common indication for cardiac 
transplantation. Myocarditis is also identified as the 
cause of sudden unexpected death in young patients. 
Nevertheless, this condition remains somewhat 
enigmatic from the perspective of diagnosis, and there 
exists considerable variation in management 
practices. This article aims to summarise the current 
research and emphasise pertinent aspects of 
myocarditis for the general paediatrician [2]. 
 
 
Definition 
 
In 1995, the World Health Organization 
created the following definition: ‘‘Inflammatory 
cardiomyopathy is defined by myocarditis in 
association with cardiac dysfunction. Myocarditis is an 
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inflammatory disease of the myocardium and is 
diagnosed by established histological/immunological, 
and immunohistological criteria. Idiopathic, 
autoimmune, and infectious forms of inflammatory 
cardiomyopathy are recognised’’ [3].
 
Notably, this 
inflammation occurs in the absence of ischemia. 
 
 
Epidemiology 
 
The true incidence of myocarditis in the 
pediatric population is difficult to measure due to the 
wide variety of presentations and the lack of 
diagnostic protocols [4].
 
Over half of all cases of 
myocarditis occur in patients below the age of 40 
years. A post-mortem analysis showed a prevalence 
of 3.5-5% [5], but the rate of clinically significant cases 
more closely approximates 0.1-0.6% [6]. Patients of 
all ages may be affected, but the majority of cases 
occur in infants and teenagers; more than one-half of 
all cases are seen in the first year of life [7]. The 
reason for this unusual bimodal age distribution is 
currently unclear. By screening electrocardiograms in 
Japan, the approximate incidence of myocarditis is 
estimated to be about 7 per 60,000 (0.012%) 
asymptomatic children [8], [9]. A recent retrospective 
review reported the prevalence of myocarditis to be 
0.5 cases per 10,000 emergency department visits 
[10].
 
Children in this study were diagnosed using 
history, clinical exam, and various supportive 
investigations. An approximate incidence may lie 
between 0.15% and 0.6% in the overall population 
based on postmortem histology [11]. As myocarditis is 
also associated with sudden cardiac death in young 
patients, this may further confound estimates of 
incidence and prevalence [12], [13]. 
 
 
Aetiology 
 
The multiple etiologies of myocarditis are 
summarised in Table 1 [14]. It is caused primarily by 
numerous infectious agents, but it may also 
accompany autoimmune disease, hypersensitivity 
reactions, and toxins [15]. Infectious exposures, 
especially viruses, account for the vast majority of 
pediatric myocarditis; in Canada and the United 
States, whereas globally the most common cause is 
Trypanosoma cruzi (Chagas disease) [16]. The 
majority of paediatric cases are believed to be due to 
adenoviruses and enteroviruses, such as 
coxsackieviruses A and B, parvovirus, echovirus, and 
poliovirus [17], [18]. The relative frequency of cases 
related to these viruses is variable, and there is much 
discussion as to which is more common. In the past, 
enteroviruses, especially the coxsackieviruses, were 
considered the most common aetiology. A recent 
study suggested that adenovirus may be a more 
significant pathogen than previously recognised [19]. 
Among patients given a clinical diagnosis of 
myocarditis, those with positive adenovirus 
polymerase chain reaction were less likely to have a 
corresponding histological diagnosis of acute 
myocarditis compared with the enterovirus group 
(40% versus 79%) [20]. This suggests that adenovirus 
is associated with a lesser degree of inflammation in 
the myocardium. This may suggest a higher 
prevalence of adenovirus than suspected [21].
 
 A subsequent study reviewed etiologies for 
biopsy-confirmed myocardial inflammation and found 
parvovirus B 19 to be the most common, followed by 
enterovirus, human herpesvirus 6, and then 
adenovirus [21], [22]. Following the H1N1 Influenza A 
pandemic, there were case reports of associated 
myocarditis. Of the 80 confirmed viral infections 
reported by one group, there were four cases of 
associated myocarditis, three of which presented with 
fulminant myocarditis: one patient had a fatal outcome 
due to acute atrioventricular block, and two required 
extracorporeal membrane oxygenation support due to 
severely reduced left ventricular systolic function.
23,24
 
Extracorporeal membrane oxygenation is 
implemented in many paediatrics tertiary centres for 
either respiratory failure or cardiac compromise in 
cases of H1N1 infection. Further population data are 
required to clarify the clinical course of H1N1-
associated myocarditis [25].
 
Table 1: Various causes of myocarditis 
Aetiology  Examples 
Infectious Viral: adenoviruses, echoviruses, enteroviruses (eg, 
coxsackieviruses), herpesviruses (human cytomegalovirus, 
Epstein-Barr virus, human herpesvirus 6), hepatitis C virus, human 
immunodeficiency virus, influenza A virus, parvovirus B19 
Bacterial: chlamydia, Corynebacterium diphtheria, Klebsiella, 
Salmonella, Legionella, Mycobacterium tuberculosis, mycoplasma, 
staphylococcus, streptococcus A, Streptococcus pneumonia, 
Tryponema Pallidum, Haemophilus influenzae 
Fungal: actinomyces, aspergillus, candida, cryptococcus 
Helminthic: Echinococcus granulosus, Trichinella spiralis 
Protozoal: Toxoplasma gondii, Trypanosoma cruzi 
Rickettsial: Coxiella burnetti, Rickettsia typhi 
Spirochetal: Borrelia burgdorferi, leptospira, Treponema pallidum 
Autoimmune 
diseases 
Celiac disease, Churg-Strauss syndrome, Crohn disease, 
dermatomyositis, giant cell myocarditis, hypereosinophilic 
syndrome, Kawasaki disease, lupus erythematodes, 
lymphofollicular myocarditis, rheumatoid arthritis, sarcoidosis, 
scleroderma, ulcerative colitis 
Hypersensitivity 
reactions 
Penicillin, ampicillin, cephalosporins, tetracyclines, sulfonamides, 
antiphlogistics, benzodiazepines, clozapine, loop and thiazide 
diuretics, methyldopa, smallpox vaccine, tetanus toxoid, tricyclic 
antidepressants 
Toxic reactions to 
drugs 
Amphetamines, anthracyclines, catecholamines, cocaine, 
cyclophosphamide, 5-fluorouracil, phenytoin, trastuzumab 
Toxic Amitriptyline, Amphotericin B, Cannabis, Carbon monoxide, 
Cyclophosphamide, Electric shock, Ethanol, Hymenoptera, 
Isoniazid, Lead, Lidocaine, Methyldopa, Nonsteroidal anti-
inflammation, Phenytoin, Snake or scorpion venom,  
Others Arsenic, copper, iron, radiotherapy, thyrotoxicosis 
 
 
Pathology and pathophysiology 
 
There are several proposed mechanisms of 
myocardial injury in viral myocarditis [4], [5], [21]. The 
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inflammatory process begins when the body's immune 
cells (the cells that fight infection) penetrate the heart 
tissue. These immune cells become activated and 
produce chemicals that can cause damage to the 
heart muscle cells. There are thickening and swelling 
of the heart muscle. All four chambers of the heart 
may be affected and become enlarged [24], [25]. 
These include the excessive immune-mediated 
destruction of the myocardium by infiltrating immune 
cells targeting the infected cardiomyocytes; 
autoimmune-mediated destruction of cardiac cells by 
circulating autoantibodies; and direct virus-induced 
cardiac myocyte injury. It is proposed that three 
phases of viral myocarditis exist, beginning with a 
period of viral replication, followed by acute injury to 
the myocytes, and subsequent evolution of dilated 
cardiomyopathy, associated with profound alteration 
in the extracellular matrix of heart muscle [4], [8], [9], 
[22].  
Mechanism of developing the myocarditis 
after infection of cardiac endothelial cells or cardiac 
myocytes by virus leads to direct cellular damage. A 
subsequent innate and adaptive immune response 
develops that can evolve into resolution and healing 
or dilated cardiomyopathy resulting from severe initial 
injury, persistent inflammation, or persistent viral 
infection. Adapted from Schultheiss et al., [5] with 
permission of the publisher. 
Damaged muscle cells may heal over time, or 
there may be cell death followed by scar formation. If 
this process is extensive and a large portion of the 
heart is involved, the heart's ability to pump blood is 
impaired. As a result, the key organs and tissues in 
the body do not get enough oxygen and nutrients and 
cannot get rid of waste products. This is often referred 
to as congestive heart failure. Up to 27% of dilated 
cardiomyopathy cases in children may be attributable 
to viral myocarditis [23], [24]. 
 
 
Clinical presentation 
 
Cardiovascular syndromes observed with 
pediatric myocarditis are sudden death, arrhythmias, 
chest pain, myocardial infarction, acute heart failure 
with a dilated cardiomyopathy phenotype. 
 
Sudden death 
Sudden death in the pediatric population is 
commonly associated with myocarditis, and it may be 
the presenting feature of myocarditis, and in these 
cases, the diagnosis is often made histologically. It is 
suggested that some cases may be the result of 
inflammatory infiltrates that act as arrhythmogenic 
foci, leading to fatal arrhythmia. Studies of sudden 
infant death syndrome have linked infection with 
viruses such as enterovirus, adenovirus, parvovirus 
B19, and Epstein-Barr virus and myocarditis to 
sudden infant death syndrome victims [25], [26]. A 
broad clinic-pathological classification system can be 
used in which there are four categories of myocarditis 
in the setting of a viral illness. Myocarditis accounted 
for ≈ 9% of sudden deaths in young athletes in the 
United States in whom a confirmed cardiovascular 
event was documented. Despite the existence of 
echocardiographic and endomyocardial biopsy criteria 
for myocarditis and resulting cardiomyopathy, expert 
opinion currently suggests that the diagnosis of 
‘‘probable’’ myocarditis is based on clinical judgement 
[27]. 
 
Arrhythmias 
Symptoms such as palpitations and syncope 
occur in pediatric myocarditis patients even in the 
absence of heart failure or demonstrable reduction of 
left ventricular function. Pediatric ventricular 
arrhythmias in structurally normal hearts and 
ventricular tachyarrhythmias in athletes have been 
associated with myocarditis [28], [29]. Myocarditis 
should always be considered in a child with acquired 
complete heart block. Lyme carditis
 
and Chagas 
disease
 
have been associated with complete heart 
block. Although the majority of children may recover 
atrioventricular conduction, most patients need 
implantation of a permanent pacemaker [30], [31], 
[32].  
 
Chest Pain/Myocardial Infarction 
More than 20 years ago, it was recognised in 
adults and children that myocarditis might mimic 
myocardial infarction with severe symptomatic chest 
pain, characteristic ECG findings, and elevation of 
serum creatinine kinase, in the presence of normal 
coronary angiograms. Coronary spasm has been 
observed with this presentation in adults [33], 
[34]. Parvovirus B19 has been found in the 
myocardium of such patients, as well as adenovirus 
and Epstein-Barr virus [35].
 
In a study of 4436 patients 
presenting to a pediatric emergency department with 
chest pain, 24 had a confirmed cardiac origin, of 
whom four were diagnosed with myocarditis [36].
 
A 
recent study of pediatric patients, presenting with 
myocarditis and a chest pain/myocardial infarction 
pattern, found that all had elevations of cardiac 
troponin I (peak range, 6.54–64.59 ng/mL), in the 
presence of normal values of erythrocyte 
sedimentation rate and C-reactive protein. 
Echocardiograms demonstrated a mild reduction in 
left ventricular function in 57% of the patients, and 5 of 
6 patients demonstrated cMRI findings consistent with 
myocarditis. The prognosis was good with a resolution 
of cardiac abnormalities within a few weeks, similar to 
the adult experience [37], [38].
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Acute heart failure with dilated 
cardiomyopathy phenotype 
The classic presentation of myocarditis is the 
development of symptoms of heart failure with a 
dilated cardiomyopathy phenotype a few weeks after 
a history compatible with a viral illness, including 
fever, myalgias, and respiratory or gastrointestinal 
symptoms. Myocarditis accounts for 30% to 35% of 
children with dilated cardiomyopathy phenotypes in 
the Australian and North American pediatric 
cardiomyopathy registries and for 22% of new-onset 
left ventricular dysfunction in the United Kingdom [38, 
[39], [40]. 
Fulminant myocarditis is a distinct subset of 
acute myocarditis characterized by heart failure with 
severe hemodynamic compromise requiring inotropic 
or mechanical circulatory support and at least 2 of the 
following criteria: fever, distinct onset of heart failure 
symptoms within a 1- to 2-day period, and a history 
consistent with viral illness within the 2 weeks before 
hospitalization. Fulminant myocarditis is associated 
with symptoms of significant left ventricular 
dysfunction and unexpected cardiac failure within 2–3 
weeks of the onset of viral infection [40], [41].
 
Fulminant myocarditis has been described in children 
with mortalities varying from 48.4% in Japan to 9% in 
France. Despite the severe presentation, outcomes 
are substantially better than in adults with acute 
myocarditis. Acute myocarditis presenting with severe 
heart failure, arrhythmias, and lack of responsiveness 
to supportive care after 1 to 2 weeks leads to concern 
for giant cell myocarditis, which can be diagnosed by 
biopsy and has a grim prognosis, although is 
responsive to immunosuppression [42]. 
Acute myocarditis in children has been 
associated with a good prognosis with a good chance 
for ultimate recovery of left ventricular dysfunction 
[16], [17]. Within the North American Pediatric 
Cardiomyopathy Registry (PCMR), 372 myocarditis 
patients diagnosed by biopsy (n = 119) or clinical 
criteria (n = 253) were compared with 1123 patients 
diagnosed with idiopathic dilated cardiomyopathy. 
Outcomes were similar in the biopsy and clinically 
diagnosed myocarditis patients and substantially 
better than in children diagnosed with idiopathic 
dilated cardiomyopathy. These results are similar to 
an estimated 58% spontaneous recovery in acute 
adult myocarditis gleaned from an adult meta-analysis 
[43].
 
‘‘Subacute myocarditis’’ can be described as 
moderate left ventricular dysfunction and has less 
distinct clinical features of the disease. 
‘‘Chronic active myocarditis’’ is associated 
with moderate left ventricular dysfunction, indistinct 
symptoms, and endomyocardial biopsy reveals 
ongoing inflammation, myocardial damage, and active 
scar tissue. 
‘‘Chronic persistent myocarditis’’ is described 
in the setting of normal left ventricular function and 
palpitations or atypical chest pain, with persistent 
inflammation on biopsy [44].
 
Myocarditis in children is associated with a 
high rate of congestive heart failure, hospitalisation, 
intensive care unit stay, and use of inotropic support 
at the time of diagnosis compared with children with 
idiopathic dilated cardiomyopathy.
 
A recent study of 
hospitalised patients in the United States
 
found that 
nearly half of the patients required inotropic support, 
37.5% required mechanical ventilation, and 7.4% 
required extracorporeal membrane oxygenator 
(ECMO) support [23], [45].  
 
 
Diagnosis 
 
History and physical examination 
The diagnosis of pediatric myocarditis is 
especially challenging because of the variable clinical 
presentation, ranging from asymptomatic patients with 
only subtle findings on an electrocardiogram to 
fulminant cardiac failure and sudden death. Diagnosis 
remains largely based on clinical judgement, 
supported by ancillary tests; therefore, a high index of 
suspicion is necessary. Clinical features are often 
those of congestive cardiac failure and myocarditis is 
identified as the most common cause of new-onset 
cardiac failure in previously well children [22], [46].
 
Even patients with mild symptoms are at risk of 
deterioration, and therefore early diagnosis is 
important in establishing appropriate monitoring and 
supportive care.  
The majority of patients present with a resting 
tachycardia, but other cardiac-specific signs such as 
pallor, hypotension, oedema, and hepatomegaly occur 
in only a minority of cases. Chest pain, syncope, and 
palpitations may also be presenting complaints. Fever 
may or may not be present. There are several 
paediatric studies that have examined the most 
common signs and symptoms of patients with 
myocarditis. Shortness of breath, respiratory distress, 
or an abnormal respiratory exam were commonly 
observed [22], [47]. In two studies, 84% of patients 
required more than one visit to a physician within 14 
days before the diagnosis of myocarditis or dilated 
cardiomyopathy was made [23].  
Children were often given an initial diagnosis 
of asthma or pneumonia [5]. Resting tachycardia is 
also an important subtle feature, and although this is 
not always a consistent finding, it may be the only 
finding of mild disease [5], [48]. Isolated vomiting is 
observed, and this may be due to gut ischaemia 
secondary-to-low cardiac output. Isolated 
gastrointestinal symptoms of anorexia, abdominal 
pain, and vomiting may also occur. Hepatomegaly is a 
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common feature on physical exam and may present 
as non-specific abdominal pain [5], [23].
 
In contrast to 
adults with myocarditis, chest pain is seldom reported 
in younger children though it may be a more common 
feature in adolescents. A case series of several 
teenage patients diagnosed with myocarditis 
described symptoms of severe chest pain, in 
combination with elevated cardiac troponin-I, ST-
segment, and T-wave changes [24], [48]. 
 
 
Investigations  
  
Despite many diagnostic modalities, suspicion 
of myocarditis is mainly based on clinical criteria. 
Diagnostic workup should include baseline 
investigations listed in Table 3. Abnormal troponin 
levels may support a diagnosis of myocarditis, but 
there are limited data in the current pediatric literature 
[29], [49]. An elevated creatine kinase level may also 
be observed in myocarditis, although it is a non-
specific marker.  
It has been suggested that, in comparison 
with creatine kinase, cardiac troponin-T may provide 
better sensitivity for detecting micronecrosis in 
myocarditis because of a proportionally higher and 
longer-lasting elevation of serum levels [30], [50]. In 
the Myocarditis Treatment Trial, elevations of cardiac 
troponin I occurred more frequently than did 
elevations of creatine kinase muscle and brain 
subunits in patients with biopsy-proven myocarditis 
[31], [51]. There was one pediatric study that 
illustrated a cut-off point for a cardiac troponin T level 
of 0.052 nanograms per millilitre for diagnosing acute 
myocarditis with a sensitivity of 71% and specificity of 
86%, although there was no correlation between 
cardiac troponin T level and ejection fraction [32], [52].  
Use of the N-terminal segment of the B-type 
natriuretic peptide prohormone levels may be helpful 
in the setting of myocarditis, especially concerning 
recovery. In one study, elevated N-terminal B-type 
natriuretic peptide levels correlated well with clinical 
status and echocardiographic findings in patients with 
dilated cardiomyopathy or myocarditis [33], [53], [54]. 
N-terminal B-type natriuretic peptide levels had 78% 
sensitivity and 100% specificity for the diagnosis of 
persistent left ventricular dysfunction. Patients who 
recovered had N-terminal B-type natriuretic peptide 
levels that were within normal limits [55].  
Chest X-ray findings often include 
cardiomegaly and may demonstrate pulmonary 
oedema, infiltrates, or pleural effusions [6], [34].  
Electrocardiogram ECGs are virtually always 
abnormal in children with myocarditis, found in over 
93% of patients but a normal ECG does not rule out 
the possibility of the disease [23], [56]. ECG 
abnormalities, however, are widely variable, and there 
is not one specific abnormality that occurs with 
enough frequency to be a specific marker. The most 
common abnormalities include sinus tachycardia, 
criteria for ventricular hypertrophy, ST segment, and 
T-wave abnormalities. Premature contractions and a 
wide variety of tachyarrhythmias and 
bradyarrhythmias occur in myocarditis, including 
complete atrioventricular block, atrial and ventricular 
delays and prolongation of QT intervals may also 
occur. The combination of an electrocardiogram with 
chest X-ray in the setting of possible myocarditis has 
very good sensitivity for the diagnosis [4], [13], [57].
 
Echocardiographic findings may include 
increased ventricular end-systolic or diastolic 
dimensions, reduced shortening or ejection fractions, 
atrioventricular valve regurgitation, and regional wall 
motion abnormalities [36]. Echocardiography is also 
important to rule out coronary abnormalities as a 
cause of depressed myocardial function. Abnormal 
right ventricular function on echo may be associated 
with an increased likelihood of adverse outcomes 
including cardiac transplantation or death [37]. Other 
methods of non-invasive imaging are being 
investigated in the setting of myocarditis.  
Nuclear medicine techniques have not been 
used widely in paediatrics, in part due to concerns of 
excessive radiation exposure for children [38].
 
Cardiovascular magnetic resonance imaging 
is a widely accepted tool to assess myocarditis. This 
technique provides a detailed not only functional and 
morphological assessment of the heart, but also 
reliable visualisation of tissue markers of myocarditis 
including oedema, inflammation, and fibrosis [41], 
[43]. Previously, oedema could not be well imaged; 
however, cardiac magnetic resonance is now able to 
visualise myocardial oedema without using radiation 
or contrast agents. Currently, cardiac magnetic 
resonance may be considered the single best non-
invasive imaging study for this indication, and 
standardised protocols for cardiac magnetic 
resonance imaging of myocarditis are available [42]. 
In acute myocarditis, cardiac magnetic resonance 
assessment of myocardial oedema is performed using 
T2-weighted short TI inversion recovery imaging in 
which regions of myocardial oedema appear bright, 
whereas fat and blood signals are suppressed. 
The sensitivity and specificity of T1-weighted 
images in patients with suspected chronic myocarditis 
were 62% and 86%, respectively, using 
immunohistological methods as the gold standard 
[39]. Similar to myocardial oedema, early 
enhancement normalises approximately 4 weeks after 
the clinical presentation and therefore may be used as 
a marker of the acuity of myocardial injury [23]. In a 
small proportion of patients, the early enhancement 
may persist and is correlated to reduced cardiac 
function. It is not currently known whether persistently 
elevated early enhancement truly reflects an ongoing 
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viral infection. The cardiac magnetic resonance 
technique of gadolinium late enhancement allows 
visualisation of myocardial necrosis and fibrosis 
associated with myocarditis.
58
 Gadolinium 
accumulates in regions of fibrosis, leading to 
increased signal intensity in late enhancement 
images. In the setting of myocarditis, the pattern of 
myocardial fibrosis varies considerably but typically 
involves patchy focal fibrosis of the sub-epicardium or 
mid-myocardial wall, rarely extending to the sub-
endocardium [41], [43]. The presence of myocardial 
fibrosis detected by cardiac magnetic resonance late 
enhancement is more common in males and younger 
patients, and the pattern of myocardial injury 
sustained in young patients tends to be more regional 
and more severe, with a higher incidence of 
irreversible myocardial scarring [28]. This pattern of 
myocardial injury may explain why younger patients 
are at risk of adverse cardiac outcomes — the 
presence of gadolinium late enhancement 4 weeks 
after the acute presentation is also correlated with 
reduced left ventricular ejection fraction and clinical 
symptomatology at 30-month follow-up [58].  
To standardise cardiac magnetic resonance 
imaging to diagnose myocarditis, the International 
Consensus Group on Cardiovascular Magnetic 
Resonance created new criteria, known as the ‘‘Lake 
Louise Criteria’’. These recommendations describe 
indications for cardiac magnetic resonance in patients 
with suspected myocarditis, cardiac magnetic 
resonance protocol standards, terminology for 
reporting cardiac magnetic resonance findings, and 
diagnostic cardiac magnetic resonance criteria for 
myocarditis. These guidelines report that the greatest 
balance of diagnostic sensitivity and specificity for 
acute myocarditis is achieved with the presence of 
any two or more of the following three criteria: 
myocardial oedema (T2 short TI inversion recovery), 
hyperaemia/capillary leak (early enhancement), or 
myocardial fibrosis (late gadolinium enhancement) 
[59], [60].  
The gold standard for the diagnosis of 
myocarditis remains endomyocardial biopsy; however, 
this approach has significant limitations [26]. 
According to the Dallas Criteria, endomyocardial 
specimens are considered diagnostic of active 
myocarditis, if routine light microscopy reveals 
infiltrating lymphocytes and myocytolysis [26]. 
Borderline or ongoing myocarditis is defined as 
lymphocytic infiltration in the absence of myocytolysis. 
A biopsy is considered negative, if both lymphocytic 
infiltration and myocytolysis are absent [27], [61].
 
 A potential reason to proceed with biopsy is 
that the presence of immune complexes and 
complement deposits supports an immune-mediated 
process; therefore, the management may differ from 
that of the case of viral infection. For example, 
immune suppression is not indicated in 
cardiomyopathy but may be worthwhile in viral 
myocarditis. A biopsy may be useful in the setting of 
eosinophilic infiltrates, which could suggest a 
hypersensitivity response to an exogenous agent. In 
this case, once the histology is confirmed, the 
offending agent can be removed, and the clinical 
picture may improve. A significant limitation of cardiac 
biopsy is that myocarditis affects the myocardium in a 
patchy fashion, and therefore negative biopsy may not 
exclude disease [62], [63].  
There remains controversy as to whether or 
not to proceed with biopsy, especially since biopsy 
can be associated with arrhythmia and perforation of 
cardiac tissue. Pediatric literature also suggests that 
the highest rate of complication occurs in patients 
being evaluated for myocarditis, as well as those 
requiring inotropic support [49], [63]. Despite the 
overall complication rate being relatively low (1-6%), 
with mortality between 0.0% and 0.4%, risk-benefit 
analysis occurs on a case-by-case basis [49], [64].
 
Table 2: Diagnostic classification for patients with myocarditis 
Criteria 
Pathological 
Confirmation 
ECG or 
Imaging 
Possible subclinical acute myocarditis 
Absent Needed 
In the clinical context of possible myocardial injury 
without cardiovascular symptoms but with at least 1 
of the following 
Biomarkers of cardiac injury raised 
ECG findings suggestive of cardiac injury 
Abnormal cardiac function on echocardiogram or 
cardiac MRI 
Probable acute myocarditis 
Absent Needed 
In the clinical context of possible myocardial injury 
with cardiovascular symptoms and at least 1 of the 
following: 
Biomarkers of cardiac injury raised 
ECG findings suggestive of cardiac injury 
Abnormal cardiac function on echocardiogram or 
cardiac MRI 
Definite myocarditis 
Needed Not needed 
Histological or immunohistological 
  
 
 
Treatment 
 
Despite improved understanding of the 
pathogenesis of myocarditis, treatment strategies 
remain controversial, and the general approach is 
supportive. The stabilisation of children who present 
with hemodynamic compromise and early involvement 
of pediatric cardiology specialists are crucial. 
Treatment of congestive cardiac failure may include 
diuretics, afterload reduction, inotropic support, 
anticoagulation, arrhythmia management, and 
ventilatory support [64], [65].  
Aggressive administration of intravenous 
fluids initially may exacerbate cardiac failure. 
Transfusions of packed red blood cells may be 
required to optimise oxygen carrying capacity.  
The use of inotropes such as dopamine, 
dobutamine, and milrinone may be necessary. 
Afterload reduction, if it can be tolerated, with 
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phosphodiesterase inhibitors such as milrinone can be 
extremely useful. It is also suggested that the early 
introduction of angiotensin-converting enzyme 
inhibitors, as well as beta-blockers, once the acute 
decompensatory phase has begun to resolve, may be 
beneficial. These medications may help prevent the 
remodelling that evolves to dilated cardiomyopathy as 
well as relieving vasospasm to some degree [17], [18]. 
In pediatric patients, carvedilol was suggested in this 
regard but has not been studied extensively [67]. 
Anticoagulation may be recommended if the ejection 
fraction is severely decreased or in the setting of atrial 
arrhythmias [55]. Some patients may require 
ventilatory support as a means of reducing cardiac 
demand. Ventilation and oxygenation may be best 
managed with continuous positive airway pressure or 
other non-invasive methods, for several reasons. 
Increased intrathoracic pressure via nasal or mask 
continuous positive airway pressure may help to 
reduce left ventricular afterload by reducing 
transmural myocardial wall tension, without causing 
the hypotension associated with pharmacologic 
afterload reduction. Intubation medications can cause 
hypotension and acute cardiovascular collapse; 
therefore, continuous positive airway pressure may 
also circumvent this and is an excellent adjunctive 
therapy for decompensated cardiac failure [43], [55]. 
Those with more severe cases of myocarditis may 
require circulatory support in the form of 
extracorporeal membrane oxygenation or ventricular 
assist devices.  
 
 
Immunomodulation, immunosuppression 
and antiviral therapy 
 
Animal studies have suggested that 
myocarditis has a 3-phased course [31]. Phase 1 
involves initial direct myocardial injury from the 
actively replicating virus or the innate immunological 
response from infection of cardiac myocytes, 
fibroblast, or endothelial cells. Phase 2 is marked by 
activation of antigen-specific immunity involving T 
cells, B cells, and antibody production. Various 
chemokines are present that may contain the 
inflammatory response but extend tissue injury. 
Development of autoantibodies and persistent T-cell 
activation can be induced by antigens intrinsic to the 
myocardium that cross-react with viral peptides 
(molecular mimicry). Ultimate outcomes may vary. 
Negative immune modulation may occur rapidly after 
the elimination of the infectious pathogens, leading to 
a cessation of the inflammatory response with a 
complete recovery or little long-term myocardial 
damage. However, phase 3 may occur in which acute 
myocarditis leads to a chronic dilated cardiomyopathy. 
This may result from severe myocardial injury caused 
by the acute event; an ongoing inflammatory, 
autoimmune process that may occur without the 
persistent presence of virus in the myocardium 
(inflammatory dilated cardiomyopathy); or ongoing 
direct injury from virus with or without a persistent 
myocardial inflammatory response (viral heart 
disease) [7], [8], [66], [67].  
An area of significant controversy involves the 
use of immune suppression and immune modulators 
in the context of myocarditis. There are large-scale 
adult studies concerning immune suppression, and 
overall the data have shown some limited, short-term 
response to these therapies. In two large adult 
prospective studies, immunosuppression including 
prednisone with or without azathioprine or 
cyclosporine was used [68], [69]. With prednisone 
alone, there was a modest improvement in left 
ventricular function in patients with evidence of 
inflammation on biopsy; however, this improvement 
was not sustained. The Myocarditis Treatment Trial 
found no significant improvement in function and no 
difference in survival when compared with controls [2], 
[70].  
Despite the existence also of a handful of 
uncontrolled studies that showed benefit with various 
immunosuppressive regimes, some meta-analyses of 
adult studies did not show a significant beneficial 
effect of immunosuppression [6], [71]. It is always 
difficult to extrapolate the findings of adult studies to 
the pediatric population. Pediatric studies are limited, 
and there are no randomised controlled trials. Many 
used prednisolone and did find some benefit, though 
not always statistically significant, by adding a second 
agent. In one trial, patients were stratified into either 
standard treatment, or given one of three 
immunosuppressive therapies, prednisolone, 
prednisolone and azathioprine, or prednisolone and 
cyclosporin A [70]. The groups receiving 
immunosuppressive treatment with a second agent, in 
addition to the prednisolone, showed improved 
hemodynamic parameters, as well as histological 
improvement in inflammation [72]. Some small case 
series suggested some clinical benefit to 
immunosuppressive treatment, again using 
corticosteroids with an additional agent; however, 
most were small, uncontrolled studies [22] A meta-
analysis of pediatric studies between 1984 and 2003 
systematically reviewed the impact of 
immunosuppressive therapy in children with 
myocarditis and overall found no consistent benefit 
[73. This included nine pediatric studies, all of which 
were small and very heterogeneous in design. Many 
of the studies were retrospective and uncontrolled, 
introducing significant bias.  
Intravenous immunoglobulin was also 
examined as a potential immunomodulating therapy to 
decrease inflammation potentially. Despite some 
studies observing a trend towards improved cardiac 
status following treatment, there are no randomised 
controlled trials using intravenous immune globulin in 
children with myocarditis. A few authors conducted a 
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comprehensive multi-database search including 
patients of all ages with myocarditis treated with 
intravenous immune globulin. They concluded that if 
there is evidence that ongoing, active infection may be 
causing persistent cardiac dysfunction, intravenous 
immune globulin may be helpful [74]. Even if post 
infectious inflammation is the most likely aetiology, 
intravenous immune globulin may still be beneficial by 
preventing the formation of cytokines [16], [17]. There 
is one multi-centre adult randomised controlled trial 
using intravenous immune globulin [75]. They found 
no significant difference in rates of survival, cardiac 
transplantation, use of ventricular assist devices, 
improvement in ventricular function, or functional 
capacity at 1 year of follow-up. A Cochrane review of 
intravenous immune globulin in dilated 
cardiomyopathy or myocarditis showed no benefit in 
adults; however, some case reports and case series 
suggested that adults treated with intravenous 
immune globulin did exhibit improved cardiac function 
[15], [16], [28], [76]. Some case reports and series in 
children have shown improved ventricular function 
and clinical improvement after high-dose intravenous 
immune globulin, however with small numbers.
77
 
Overall, it was felt that the validity of many of these 
studies was compromised due to the lack of control 
groups. There was one case report of coxsackievirus 
A19 myocarditis in which intravenous immune globulin 
was not effective, and another case series found no 
additional benefit by adding intravenous immune 
globulin to steroid treatment [78].
 
Studies using immunosuppressive or 
immunomodulating treatments, therefore, were 
difficult to translate into an effective, routine therapy 
for children or adults with myocarditis. Many patients 
with myocarditis have spontaneous improvement. It is 
difficult to know if the observed improvement after 
treatment with immunosuppression or intravenous 
immune globulin is attributable to treatment versus the 
natural course of the disease. Potentially, some 
aetiologic types of myocarditis respond differently, and 
certain histologic characteristics may make specific 
patients better responders than others [9], [11], [79]. 
Further studies are needed to determine the possible 
utility of immunosuppressive or immunomodulating 
therapy. 
 
 
Therapy for advanced heart 
failure/cardiogenic shock in pediatric 
myocarditis 
 
Acute pediatric myocarditis is commonly 
associated with severe, progressive heart failure. The 
majority of patients receives care in an intensive care 
unit at presentation and is treated with intravenous 
inotropes [80].
 
Mechanical circulatory support is 
frequently required when pharmacological therapy is 
ineffective, as reflected in evidence of elevated blood 
lactate levels and evidence of end-organ dysfunction 
[32]. Most commonly, ECMO support is used. ECMO 
is currently used in ≈ 20% of American children 
hospitalised with myocarditis [81]. Some single-centre 
studies have reported hospital discharge rates of ≈ 
80% in pediatric myocarditis requiring ECMO support, 
with ≈ 60% of the patients experiencing myocardial 
recovery. Multicenter data from the Extracorporeal 
Life Support Organization (ELSO) registry 
demonstrated a lower hospital discharge rate of 61% 
in 10 years from 1995-2006 [51], [82].
 
ECMO provides biventricular circulatory 
support but does not decompress the left ventricle. 
Patients placed on ECMO will initially demonstrate a 
stunned, left ventricle with no effective ejection, which 
can lead to a need for decompression of the left 
ventricle via a left-sided vent or atrial septostomy in as 
many as 30% of cases
 
to avoid pulmonary venous 
hypertension and pulmonary haemorrhage [83]. 
Evidence of improved left ventricular ejection usually 
appears less than a week after the initiation of ECMO. 
Although ECMO can provide effective short-term (< 2 
weeks) support, survival was < 50% in myocarditis 
patients requiring > 2 weeks of support in the ELSO 
registry. Factors associated with death on ECMO 
have included the presence of arrhythmia on 
support, the need for dialysis, and higher stages of 
end-organ hypoperfusion, as reflected in serum 
lactate, creatinine, and aspartate aminotransferase 
levels [84], [85]. In 1 centre’s experience, the absence 
of the virus in the myocardium or evidence of 
myocardial inflammation was associated with a 
greater chance for recovery [86].
 
Ventricular assist devices (VADs) have 
revolutionised the care of adults with advanced heart 
failure. VAD support, usually in the form of left 
ventricular assist devices as opposed to biventricular 
assist device support, is being increasingly
 
used in 
pediatric myocarditis [78], [87]. Continuous-flow 
VADs, used in adults, are limited to use in older 
children and adolescents, although the Heartware 
device has been used in children as small as 0.8 m
2
. 
Initial experience with the use of these devices in the 
pediatric population is favourable, with low mortality 
and morbidity rates, similar to the adult experience 
[88], [89].  
 The primary use of pediatric VADs is as a 
bridge to heart transplantation. In the Berlin EXCOR 
trial, the mortality in patients on the device was 8%, 
and 87.5% of patients placed on the device received 
transplantations. This experience is similar to the 
recent experience in pediatric patients using adult 
continuous-flow VADs [90].
 
The overall mortality rate 
in patients on the device in the United States during 
the period of the trial was 26% with a transplantation 
rate of 67%, reflecting the ability of centres to use the 
Berlin EXCOR on a compassionate-use basis during 
the conduct of the trial [91], [92]. Lower patient weight 
(especially < 5 kg), elevated serum bilirubin, lower 
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estimated glomerular filtration rate, and use of 
biventricular assist device support was associated 
with mortality with the device. These encouraging 
outcome results were tempered by high rates of 
neurological adverse events (29%, primarily 
thromboembolic stroke), major bleeding (44%), and 
major infection (44%) [93]. 
 
 
Outcomes and prognosis 
 
As described, it is difficult to estimate the true 
incidence and prevalence of myocarditis because of 
the broad spectrum of symptoms. It is said that the 
prognosis for children with viral myocarditis tends to 
be more positive than the outcomes with dilated 
cardiomyopathy [2], [88]. Survival rates for paediatric 
patients with myocarditis can be as high as 93% [81]. 
However, a large, multi-centre study including all age 
groups showed that there was significant mortality in 
neonates and infants (33-45% survival, 23-32% 
improvement) with better outcomes in children 
between 1 and 18 years of age (78-80% survival, 46-
67% improvement) [18].  
A study of 28 children with a diagnosis of 
myocarditis also observed that only 17 survived to 
hospital discharge with variable degrees of improved 
heart function, whereas the remaining 11 patients 
developed intractable cardiac failure leading to 
cardiac transplant listing (seven cases) or death (four 
cases) [45]. Predictors of a poor outcome were found 
to be ejection fraction less than 30%, shortening 
fraction less than 15%, left ventricular dilatation, and 
moderate-to-severe mitral valve regurgitation.98 The 
authors of several case series involving children 
requiring mechanical support for myocarditis have 
reported survival rates of 67-83% [67], [78], [79]. An 
updated review of the extracorporeal membrane 
oxygenation registry revealed a survival rate of 61% 
for children supported through acute myocarditis [91]. 
This is comparable to, and perhaps better than, 
survival rates of children supported with 
extracorporeal membrane oxygenation after repair or 
palliation of congenital cardiac disease, in which 
survival rates range between 37% and 42% [86]. 
Hetzer reported that of 21 children supported with the 
Berlin Heart Excor device for myocarditis or 
cardiomyopathy, 90% survived to hospital discharge 
[87]. Collective experience with ventricular assist 
devices in this setting, however, is quite limited. The 
prognosis in biopsy-proven myocarditis may depend 
on the severity of symptoms, histologic classification, 
and biomarkers. Acute fulminant myocarditis is 
associated with better overall survival [56], [93]. Giant 
cell myocarditis, although rare, is associated with 
especially poor outcomes and a reported median 
duration of survival, if untreated, of 5.5 months [81]. It 
also carries an 89% rate of death or transplant. 
Myocarditis may account for nearly half of all children 
with dilated cardiomyopathy [84], [91]. The outcomes 
for patients with acute viral myocarditis are much 
better than cases with established dilated 
cardiomyopathy [92]. For this reason, a high index of 
suspicion for the disease, and early effective 
supportive care are crucial. Myocarditis remains a 
relatively common indication for transplant listing. 
Overall, 1-8% of patients with acute 
myocarditis eventually go on to transplant [25]. Owing 
to the potential for recovery, even with severe disease 
at presentation, patients are not typically listed for 
cardiac transplant unless a recovery is considered 
extremely unlikely despite reasonable management 
and a period of observation. 
 
 
Conclusions 
 
Acute myocarditis comprises a wide clinical 
spectrum including the asymptomatic patient with 
subclinical myocardial dysfunction to severe cardiac 
failure or sudden cardiac death. In paediatrics, the 
symptoms and signs can mimic many other common 
diseases and a high index of clinical suspicion is 
imperative. Treatment of myocarditis remains 
supportive and should be initiated even before 
solidifying the diagnosis. Biopsy remains the gold 
standard for diagnosis; however, it has significant 
limitations. Cardiac magnetic resonance imaging has 
become a widely accepted non-invasive imaging 
modality for myocarditis and standardized protocols 
are now available for myocarditis. There exist 
controversial data and no consensus with respect to 
immunosuppressive or immunomodulating therapy for 
myocarditis. Similarly, there is no foundation of 
evidence to indicate a routine treatment strategy other 
than standard cardiac failure management for these 
patients. Most patients with myocarditis have 
spontaneous improvement in their cardiac function 
and symptoms; however, there remains significant 
morbidity and mortality associated with this condition. 
Additional studies are a necessity to clarify the most 
appropriate management options in pediatrics to 
improve outcomes. 
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